<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="152294">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01117454</url>
  </required_header>
  <id_info>
    <org_study_id>100472</org_study_id>
    <nct_id>NCT01117454</nct_id>
  </id_info>
  <brief_title>Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia</brief_title>
  <official_title>A Prospective Randomized Crossover Trial of Oral Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether the addition of oral flecainide to standard
      therapy will reduce ventricular ectopy on exercise test compared to placebo plus standard
      therapy in patients with Catecholaminergic Polymorphic Ventricular Tachycardia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) is a genetic arrhythmia
      syndrome characterized by frequent ventricular ectopy and polymorphic, classically
      bidirectional ventricular tachycardia with physical or emotional stress, which also carries
      a risk of ventricular fibrillation and sudden death, despite no structural heart
      abnormality. Treatment consists of beta-blockers and/or calcium channel blockers, but up to
      30% of patients require implantable cardioverter-defibrillators (ICDs) due to recurrent
      symptoms on medical therapy. In an animal model, flecainide was found to directly target the
      molecular defect in CPVT. In a retrospective clinical study in patients with CPVT we have
      seen improvement of ventricular ectopy on exercise tests when flecainide is added to
      standard therapy. We propose a prospective trial of flecainide added to standard therapy in
      CPVT patients to test the hypothesis that flecainide will reduce ventricular ectopy on
      exercise testing compared to placebo plus standard therapy.

      This will be a single-blind (blinded subjects) randomized cross-over study, in which each
      patient will receive treatment A (flecainide or placebo) for at least 3 months and, after a
      1 week wash-out, treatment B (placebo or flecainide) for at least 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ventricular ectopy and VT during exercise treadmill testing</measure>
    <time_frame>5 years</time_frame>
    <description>Hypothesis: the addition of oral flecainide to standard therapy will reduce ventricular ectopy and/or VT on treadmill exercise treadmill testing in patients with CPVT, compared to placebo plus standard therapy.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Catecholaminergic Polymorphic Ventricular Tachycardia</condition>
  <arm_group>
    <arm_group_label>Flecainide then placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In this crossover study, half of the subjects will be randomized to flecainide plus standard therapy first, then crossover to placebo plus standard therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo then flecainide</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In this crossover study, half of the subjects will be randomized to placebo plus standard therapy first, then crossover to flecainide plus standard therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>flecainide</intervention_name>
    <description>oral flecainide will be added to standard therapy with the dose titrated to achieve a serum level between 0.5-0.8 mcg/ml</description>
    <arm_group_label>Flecainide then placebo</arm_group_label>
    <arm_group_label>Placebo then flecainide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinical diagnosis of CPVT, based on:

             A. reproducible polymorphic or bidirectional ventricular tachycardia with exercise OR
             B. Ventricular ectopy on exercise test with RYR2 or CASQ2 mutation

          2. Functioning ICD in place

          3. On stable dose of standard therapy defined as the maximal tolerated dose of
             beta-blocker and may include a calcium channel blocker

        Patients on flecainide or mexiletine are also eligible for enrollment after a 1 week
        &quot;washout&quot; period during which flecainide or mexiletine is discontinued, and standard
        therapy alone is used.

        Exclusion Criteria:

          1. Females who are pregnant or plan to be pregnant during the study period

          2. Children &lt; 5 years of age

          3. Patients unable to perform treadmill exercise

          4. Patients with significant structural heart disease

          5. Patients with features consistent with Andersen-Tawil syndrome A. Periodic paralysis
             or unexplained weakness B. Dysmorphic facies C. Known KCNJ2 mutation

          6. Patients with known hypersensitivity to flecainide

          7. Patients on amiodarone

          8. Patients not expected to comply with follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prince J Kannankeril, MD, MSCI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook Children's Hospital</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <reference>
    <citation>Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE, Duff HJ, Roden DM, Wilde AA, Knollmann BC. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med. 2009 Apr;15(4):380-3. doi: 10.1038/nm.1942. Epub 2009 Mar 29.</citation>
    <PMID>19330009</PMID>
  </reference>
  <reference>
    <citation>van der Werf C, Kannankeril PJ, Sacher F, Krahn AD, Viskin S, Leenhardt A, Shimizu W, Sumitomo N, Fish FA, Bhuiyan ZA, Willems AR, van der Veen MJ, Watanabe H, Laborderie J, Haïssaguerre M, Knollmann BC, Wilde AA. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol. 2011 May 31;57(22):2244-54. doi: 10.1016/j.jacc.2011.01.026.</citation>
    <PMID>21616285</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 11, 2016</lastchanged_date>
  <firstreceived_date>May 4, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Prince Joseph Kannankeril</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Catecholaminergic Polymorphic Ventricular Tachycardia</keyword>
  <keyword>implantable cardioverter-defibrillator</keyword>
  <keyword>flecainide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Flecainide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
